H
Henry Masur
Researcher at National Institutes of Health
Publications - 414
Citations - 56261
Henry Masur is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Pneumocystis carinii & Pneumonia. The author has an hindex of 105, co-authored 402 publications receiving 52273 citations. Previous affiliations of Henry Masur include Burroughs Wellcome Fund & Memorial Sloan Kettering Cancer Center.
Papers
More filters
Journal ArticleDOI
Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection: An Open-Label, Nonrandomized Trial.
Anita Kohli,Sarah Kattakuzhy,Sreetha Sidharthan,Amy Nelson,Mary Ann McLaughlin,Cassie Seamon,Eleanor Wilson,Eric G. Meissner,Zayani Sims,Rachel Silk,Chloe Gross,Elizabeth Akoth,Lydia Tang,Angie Price,Tim A. Jolley,Benjamin Emmanuel,Michael A. Proschan,Gebeyehu Teferi,Jose Chavez,Stephen Abbott,A. Osinusi,Hongmei Mo,Michael A. Polis,Henry Masur,Shyam Kottilil +24 more
TL;DR: In this paper, a clinical trial was conducted to determine factors predictive of sustained virologic response (SVR) to 4 weeks of DAA treatment in patients with stage F0 to F2 liver fibrosis.
Journal Article
Use of interleukin-2 in patients with acquired immunodeficiency syndrome.
H C Lane,J P Siegel,Alain H. Rook,Henry Masur,Edward P. Gelmann,Gerald V. Quinnan,Anthony S. Fauci +6 more
TL;DR: Patients with acquired immunodeficiency syndrome were treated with a natural product, highly purified human interleukin-2, and immunologic changes during the study included a decrease in the number of circulating T8 lymphocytes, increased skin test reactivity, and a decline in serum immunoglobulin levels.
Journal ArticleDOI
Diagnosis of Pneumocystis carinii pneumonia by multiple lobe, site-directed bronchoalveolar lavage with immunofluorescent monoclonal antibody staining in human immunodeficiency virus-infected patients receiving aerosolized pentamidine chemoprophylaxis.
Stewart J. Levine,Daniel Kennedy,James H. Shelhamer,Andrea Kovacs,Irwin M. Feuerstein,Vee J. Gill,Frida Stock,Diane Solomon,C. Thomas Boylen,Henry Masur,Frederick P. Ognibene +10 more
TL;DR: This study assessed whether the yield of a single middle or lower lobe BAL could be increased by the utilization of two techniques: indirect immunofluorescent staining with a combination of two murine monoclonal anti-Pneumocystis antibodies in addition to routine toluidine blue O and cytopathologic staining and multiple lobe, site-directed BAL.
Journal ArticleDOI
Interferon-related leukocyte inclusions in acquired immune deficiency syndrome: localization in T cells.
Philip M. Grimley,Yuan-Hsu Kang,Winston R. Frederick,Alain H. Rook,Mery Kostianovsky,Joseph Sonnabend,Abe M. Macher,Gerald V. Quinnan,Robert M. Friedman,Henry Masur +9 more
TL;DR: Blood samples from a series of patients with Kaposi's sarcoma or infectious complications of the acquired immunodeficiency syndrome and from 18 homosexual contacts of AIDS patients were screened for interferon-related tubuloreticular inclusions (TRI) in circulating leukocytes, demonstrating localization of TRI in T suppressor/cytotoxic cells was demonstrated with monoclonal anti-Leu 2a antibodies.
Journal ArticleDOI
Convalescent Plasma for the Treatment of COVID-19: Perspectives of the National Institutes of Health COVID-19 Treatment Guidelines Panel.
Alice K. Pau,Judith A. Aberg,Jason V. Baker,Pamela S. Belperio,Craig M. Coopersmith,Page Crew,Birgit Grund,Roy M. Gulick,Carly Harrison,Arthur Y. Kim,H. Clifford Lane,Henry Masur,Virginia Sheikh,Kanal Singh,Jinoos Yazdany,Pablo Tebas +15 more
TL;DR: Members of the National Institutes of Health CO VID-19 Treatment Guidelines Panel provide their views regarding use of convalescent plasma for treating COVID-19.